Arrowstreet Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Arrowstreet Capital’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$179K	Sell	29,181 -212,249	-88%	-$1.39M	﹤0.01%	1855
2026 Q1	$1.67M	Buy	+241,430	New	+$1.86M	﹤0.01%	1441
2023 Q4	–	Sell	-29,778	Closed	-$129K	–	1567
2023 Q3	$129K	Buy	+29,778	New	+$165K	﹤0.01%	1213
2022 Q2	–	Sell	-101,763	Closed	-$1.15M	–	1443
2022 Q1	$1.15M	Sell	101,763 -162,766	-62%	-$2.14M	﹤0.01%	910
2021 Q4	$4.15M	Sell	264,529 -77,714	-23%	-$1.35M	0.01%	859
2021 Q3	$5.87M	Sell	342,243 -79,179	-19%	-$1.39M	0.01%	897
2021 Q2	$9.06M	Buy	+421,422	New	+$7.54M	0.01%	870
2019 Q2	–	Sell	-52,559	Closed	-$967K	–	1724
2019 Q1	$967K	Buy	+52,559	New	+$1.2M	﹤0.01%	1328
2017 Q2	–	Sell	-86,389	Closed	-$1.21M	–	1350
2017 Q1	$1.21M	Buy	+86,389	New	+$1.23M	﹤0.01%	930
2013 Q4	–	Sell	-13,044	Closed	-$143K	–	1301
2013 Q3	$143K	Buy	+13,044	New	+$139K	﹤0.01%	940

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital's VNDA Position: Q2 2026 in Review

Arrowstreet Capital reduced its Vanda Pharmaceuticals (VNDA) stake by 88% in Q2 2026, selling an estimated $1.39M and leaving 29,181 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #1855.

Arrowstreet Capital first reported a position in VNDA in Q3 2013 and has held it in 10 quarters since. The position peaked at $9.06M in Q2 2021. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

Arrowstreet Capital held 29,181 shares of Vanda Pharmaceuticals worth $179K as of Q2 2026.
Arrowstreet Capital sold 212,249 Vanda Pharmaceuticals shares in Q2 2026, an estimated $1.39M.
Vanda Pharmaceuticals made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1855 holding.
Arrowstreet Capital first reported a position in Vanda Pharmaceuticals in Q3 2013 and has held it in 10 quarters since.
Arrowstreet Capital's Vanda Pharmaceuticals position peaked at $9.06M in Q2 2021.
173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.